CJC-1295 + Ipamorelin

This isn't one drug, it's two peptides run as a pair. CJC-1295 is a long-acting GHRH analogue — it mimics the body's growth-hormone-releasing hormone, telling the pituitary to make GH. Ipamorelin is a GHRP (growth-hormone-releasing peptide) that hits a different receptor — the ghrelin receptor — to tell the pituitary to release that GH. The idea is they pull two separate levers at once. One practical wrinkle worth knowing: "CJC-1295" is sold in two forms, with and without DAC (a tag that hugely extends its half-life — days rather than minutes), and clinics often actually use the short-acting "no-DAC" version (sometimes called Mod GRF 1-29), so what's in the vial labelled "CJC-1295" varies. The name and the pairing come from anti-ageing and biohacking clinics, not from a clinical guideline.

The sales pitch is synergy: two different doorways to the same room. CJC-1295 supposedly provides a steady background lift while ipamorelin adds sharp pulses, for a "more natural" GH rhythm than injecting growth hormone directly. Ipamorelin's selling point is selectivity — it's marketed as raising GH without the cortisol and prolactin spikes seen with older, dirtier GHRPs, a claim that does trace to early animal pharmacology. The combo is pitched as the go-to stack for fat loss, lean muscle, recovery, sleep, skin and general anti-ageing, on the logic that more GH and IGF-1 means more repair and less fat. It's probably the single most requested peptide stack in private "wellness" clinics.

The mechanism is genuinely more plausible than a lot of grey-market peptides — these do raise GH and IGF-1 in short human studies, and that's reflected in their Grade C (not D). But notice the gap the sellers gloss over: the human evidence is mostly single-dose pharmacology showing hormone levels move, not trials showing people actually got leaner, more muscular or younger. There is no good human trial of the CJC-1295 + ipamorelin combination itself — the "synergy" is extrapolated from how each behaves alone and from older GHRH+GHRP class data. So you're paying for two Grade C peptides, glued together into an untested pairing, sold with Grade A confidence. Raising GH isn't automatically a free win either: it's why this whole class is banned in sport, and chronically pushing GH/IGF-1 has real trade-offs the marketing skips. Treat "anti-ageing and fat loss certainty" as the marketing claim it is, not a result.

Neither CJC-1295 nor ipamorelin is a licensed medicine in the UK — the MHRA has granted no marketing authorisation for either, for any use. They're sold as unlicensed "research chemicals" with no regulatory check on what's actually in the vial, and supplying them for human use falls foul of the Human Medicines Regulations 2012. They're not controlled under the Misuse of Drugs Act, but both sit on the WADA prohibited list (Section S2, peptide hormones and growth factors), so they're banned for anyone subject to UK Anti-Doping.